Cargando…

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study

Low dose enteric-coated aspirin (EC-ASA) is routinely used for secondary cardiovascular event prevention. However, absorption of EC tablets is poor, which can result in subtherapeutic antiplatelet effects. Phospholipid-aspirin liquid filled capsules (PL-ASA) are a novel FDA-approved immediate-releas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franchi, Francesco, Schneider, David J., Prats, Jayne, Fan, Weihong, Rollini, Fabiana, Been, Latonya, Taatjes-Sommer, Heidi S., Bhatt, Deepak L., Deliargyris, Efthymios N., Angiolillo, Dominick J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421621/ https://www.ncbi.nlm.nih.gov/pubmed/36036856 http://dx.doi.org/10.1007/s11239-022-02687-5

Ejemplares similares

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2022)

Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
por: Angiolillo, Dominick J., et al.
Publicado: (2019)

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
por: Angiolillo, Dominick J., et al.
Publicado: (2021)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2021)

When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y(12) Inhibition Induced by Ticagrelor
por: Capodanno, Davide, et al.
Publicado: (2020)

Assessing Pharmacodynamic Effects of Antiplatelet Agents With Different Mechanisms of Action
por: Schneider, David J., et al.
Publicado: (2021)

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing
por: Franchi, Francesco, et al.
Publicado: (2020)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
por: Cavallari, Larisa H., et al.
Publicado: (2018)

Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin
por: Doutremepuich, Christian
Publicado: (2012)

Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus
por: Sciacqua, Angela, et al.
Publicado: (2021)

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
por: Sweeny, Joseph M., et al.
Publicado: (2017)

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

Effects of intestinal flora on the pharmacokinetics and pharmacodynamics of aspirin in high-altitude hypoxia
por: Sun, Yuemei, et al.
Publicado: (2020)

The role of aspirin desensitization in patients with aspirin-exacerbated respiratory disease (AERD)()
por: Spies, Jonas Willian, et al.
Publicado: (2015)

Randomized, open-label, crossover trial comparing the pharmacokinetic profile of a novel oral aspirin solution and a chewed aspirin tablet
por: Atar, Dan, et al.
Publicado: (2022)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?
por: Altman, Raul, et al.
Publicado: (2004)

Small Intestinal Perforation Caused by Enteric-coated Low-dose Aspirin
por: Matsubara, Shohei, et al.
Publicado: (2022)

Are Patients Getting Their Aspirin's Worth in Ischemic Stroke?
por: Schmaier, Alec A., et al.
Publicado: (2018)

Aspirin Resistance
por: Mansour, Khaled, et al.
Publicado: (2009)

Is Aspirin Dangerous
Publicado: (1918)

Preeclampsia and aspirin
por: Ahn, Tae Gyu, et al.
Publicado: (2023)

Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
por: Langley, R E, et al.
Publicado: (2011)

Low dose aspirin and pregnancy: how important is aspirin resistance?
por: Navaratnam, K, et al.
Publicado: (2016)

Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review
por: Kedir, Hanan Muzeyin, et al.
Publicado: (2021)

The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study
por: Elshafei, Mohamed Nabil, et al.
Publicado: (2022)

Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease
por: Miller, B, et al.
Publicado: (2013)

Alleviating Aspirin-Induced Gastric Injury by Binding Aspirin to β-Lactoglobulin
por: Chen, Jin, et al.
Publicado: (2022)

Biomarkers for predicting response to aspirin therapy in aspirin‐exacerbated respiratory disease
por: Tyrak, Katarzyna E., et al.
Publicado: (2021)

Study of Pharmacodynamic and Pharmacokinetic Interaction of Bojungikki-Tang with Aspirin in Healthy Subjects and Ischemic Stroke Patients
por: Yoo, Jung-Hwa, et al.
Publicado: (2018)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

New targets for aspirin
por: Bashyam, Hema
Publicado: (2008)

The role of aspirin in carcinogenesis
por: Caine, G J, et al.
Publicado: (2002)

Aspirin and colorectal cancer.
por: La Vecchia, C., et al.
Publicado: (1997)

Aspirin-Exacerbated Asthma
por: Varghese, Mathew, et al.
Publicado: (2008)

Paradoxical Effect of Aspirin
por: Doutremepuich, Christian, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_c1ad5987ms0er9d3oo1lr8n7lu